Indication for neoadjuvant chemotherapy in patients with colorectal liver metastases based on a nomogram that predicts disease-free survival

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 21, Issue 12, 2014, Pages 881-888

  Okuno, Masayuki ^a   Hatano, Etsuro ^a   Seo, Satoru ^a   Taura, Kojiro ^a   Yasuchika, Kentaro ^a   Nakajima, Akio ^b   Yazawa, Takefumi ^c   Furuyama, Hiroaki ^d   Kawamoto, Hiroshi ^e   Yagi, Shintaro ^f   Nishitai, Ryuta ^g   Fujikawa, Takahisa ^h   Arimoto, Akira ^b   Zaima, Masazumi ^c   Yoshimura, Tsunehiro ^d   Terajima, Hiroaki ^e   Kaihara, Satoshi ^f   Manaka, Dai ^g   Tanaka, Akira ^h   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

^c SHIGA MEDICAL CENTER FOR ADULTS   (Japan)

^d TENRI HOSPITAL   (Japan)

^e Kitano Hospital   (Japan)

^f KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^g KYOTO KATSURA HOSPITAL   (Japan)

^h KOKURA MEMORIAL HOSPITAL   (Japan)

Author keywords

Colorectal liver metastases; Hepatic resection; Neoadjuvant chemotherapy; Nomogram

Indexed keywords

CA 19-9 ANTIGEN; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; BEPPU NOMOGRAM; CALIBRATION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXTERNAL VALIDITY; HUMAN; LIVER METASTASIS; LIVER SURGERY; MAJOR CLINICAL STUDY; NOMOGRAM; PREDICTION; PREOPERATIVE TREATMENT; PRIMARY TUMOR; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT INDICATION; VALIDATION STUDY; ADJUVANT THERAPY; CLINICAL TRIAL; COLORECTAL TUMOR; FEMALE; FOLLOW UP; LIVER NEOPLASMS; LIVER RESECTION; MALE; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; SECONDARY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; NEOADJUVANT THERAPY; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84912117664     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.149     Document Type: Article

References (23)

1. Eisenberg B, Decosse JJ, Harford F, Michalek J,. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer. 1982; 49: 1131-1134.
2. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009; 20: 1842-1847.
3. Steele GJ, Ravikumar TS,. Resection of hepatic metastases from colorectal metastases: biologic perspectives. Ann Surg. 1989; 210: 127-138.
4. Jaeck D, Bachellier P, Guiguet M, Boudjema K, Vaillant JC, Balladur P, et al. Long-term survival following resection of colorectal hepatic metastases. Br J Surg. 1997; 84: 977-980.
5. Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol. 2007; 14: 1151-1160.
6. Cummings L, Payes JD, Cooper GS,. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007; 109: 718-726.
7. Nathan H, de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg. 2010; 210: 755-766.
8. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009; 250: 440-448.
9. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007; 25: 4575-4580.
10. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008; 371: 1007-1016.
11. Iasonos A, Schrag D, Raj GV, Panageas KS,. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008; 26: 1364-1370.
12. Beppu T, Sakamoto Y, Hasegawa K, Honda G, Tanaka K, Kotera Y, et al. A nomogram predicting disease free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a project study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2012; 19: 72-84.
13. Polterauer S, Zhou Q, Grimm C, Seebacher V, Reinthaller A, Hofstetter G, et al. External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer. Gynecol Oncol. 2012; 125: 526-530.
14. Kattan MW, Scardino PT,. Prediction of progression: nomograms of clinical utility. Clin Prostate Cancer. 2002; 1: 90-96.
15. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361-387.
16. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29: 2011-2019.
17. Lam VW, Spiro C, Laurence JM, Johnston E, Hollands MJ, Pleass HC, et al. Systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol. 2012; 19: 1292-1301.
18. Beppu T, Miyamoto Y, Sakamoto Y, Imai K, Nitta H, Hayashi H, et al. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. Ann Surg Oncol. 2014; 21 (Suppl 3): 405-413.
19. Karanjia ND, Lordan JT, Fawcett WJ, Quiney N, Worthington TR,. Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases: a ten year study. Eur J Surg Oncol. 2009; 35: 838-843.
20. Boostrom SY, Nagorney DM, Donohue JH, Harmsen S, Thomsen K, Que F, et al. Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases. J Gastrointest Surg. 2009; 13: 2003-2010.
21. Tanaka K, Adam R, Shimada H, Azoulay D, Lévi F, Bismuth H,. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg. 2003; 90: 963-969.
22. Pawlik TM, Cosgrove D,. The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg. 2011; 15: 410-415.
23. Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B, et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011; 18: 421-430.